Biosensors International has earned CE mark approval to market its BioFreedom system, a polymer-free stent that delivers the anti-restenosis drug Biolimus A9. The Singapore-based company aims for a limited launch of the device this year and a full market release next year.
Polymer-free stent by Biosensors clears EU regulatory hurdle
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||